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Sipp et al. argue that “confusion about mesenchymal
stem cells is making it easier for people to sell
unproven treatments” [1]. The authors discuss the
explosive growth of stem cell medical tourism clinics
worldwide where legitimate scientific advancements
and the vernacular of science are misappropriated as
part of marketing strategies to promote the sales of
unproven cellular therapies branded as stem cells. We
applaud the Commentary’s effort and are grateful for
the visibility afforded to the vexing issue of stem cell
tourism. The International Society for Cellular Ther-
apy (ISCT) as well as other scholarly societies toiling
in the stem cell discovery and cell therapy space have
long been at the forefront of advocacy, education and
lobbying against the unethical and illegal selling of
unproven stem-cell therapies of all ilk and mesenchy-
mal stromal cells (MSCs) in particular. The authors
further propose that MSC terminology facilitates
deceit by medical tourism outfits by specifically
appropriating the key word “stem” as a means to
obfuscate the public. The authors propose as a rem-
edy that discovery and translational science self-iden-
tified as MSC-centric should be excluded at scientific
forums, proscribed by scholarly publications and ren-
dered ineligible for peer-reviewed “stem cell” public
funding. This is where we diverge with the Commen-
tary and its conclusions.
Clearly, stem-cell medical tourism outfits routinely
appropriate scientific terminology  like MSCs  to
give the illusion of legitimacy. We further agree that
publicly curated websites such as clinicaltrials.gov can
be coopted by unscrupulous medical tourism operations
for a wide array of cell therapy interventions outside theCorrespondence: Jacques Galipeau, MD, University of Wisconsin in Madison, 11
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including, but not limited to, MSCs.
Although various acronyms have been used in the
past to describe MSCs, it is now widely recognized
that culture-adapted progeny derived from tissue res-
ident mesenchymal progenitors are not to be con-
flated with endogenous mesenchymal stem cells. The
cell biological properties of culture-expanded MSCs
may well share some imprinted functional similarities
with the endogenous native progenitors that may or
may not be relevant in their use as an experimental
cellular pharmaceutical. Although the designation of
MSCs was as stem-cells at their inception in 1991,
their further re-designation as “stromal” accurately
reflects the meaningful differences between endoge-
nous and culture-adapted MSC products.
To reflect this distinction the ISCT issued in 2006
guidelines recommending the term “multipotent mes-
enchymal stromal cells” as a more accurate moniker,
and these guidelines have gained wide acceptance by
the scientific community [2]. The ISCT is also
engaged in educating scientific and business communi-
ties as well as the public in the potential abuse of cell
therapies including the unethical distribution for profit
of unproven cell therapies outside of institutional
review board (IRB)sanctioned and regulated clinical
trials [3]. Furthermore, an array of learned societies,
including the World Health Organization (WHO),
International Council for Commonality in Blood
Banking Automation (ICCBBA) and the International
Standards Organization (ISO), strive to adapt MSC
etymology to keep apace of requirements of consensus
terminology.
Sipp et al. appropriately state that clinical studies
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oversight that apply to any responsible clinical trial
before the cells are administered to human partici-
pants. We feel that the editorial thread pursued con-
flates the activities of medical tourism outfits with
legitimate IRB-sanctioned and regulator-licensed clini-
cal trials conducted by ethically minded industrial and
academic entities, including the National Institutes of
Health (NIH), in the conduct of clinical trials. The
discussion would have been enriched by acknowledge-
ment of recent European Union (EU) approval of
Alofisel (darvadstrocel; allogeneic Adipose Stromal
Cells (ASCs) for Crohn’s fistular disease) by the EU
that followed publication of an adequately powered
and designed industry-sponsored clinical trial required
for marketing approval of MSCs. Importantly, a num-
ber of rigorously peer-reviewed publicly and privately
funded regulator-compliant trials are underway in the
US, Europe and Asia to determine the utility of
MSCs for therapeutic use.
A rich scientific literature of MSC discovery
and well-designed clinical trials of MSCs fortherapeutic use speak to the impact of the field on
human therapeutics [4]. The implication that
studies nominally examining MSCs should be dis-
qualified from publication or funding is an ill-con-
sidered posture that runs counter to the interests
of the scientific community and public. The ISCT
will continue to maintain its support for evidence-
based translation of MSC therapies to improve
patients’ lives.References
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